This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Entyvio industry.
What is the anticipated market size of the entyvio industry over the next few years?
The entyvio market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increasing prevalence of inflammatory bowel disease, growing awareness of biologic therapies, expanding applications of vedolizumab, preference for gut-selective therapies, and increasing healthcare expenditure.
The entyvio market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to approvals for subcutaneous formulations, growing adoption of maintenance therapy, favorable clinical guidelines, limited systemic immunosuppression, and supportive insurance and reimbursement policies. Major trends in the forecast period include pipeline advancements, technological advancements, product innovation, strategic partnerships, growing investments.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19901&type=smp
What emerging drivers are expected to shape the future of the entyvio market?
The increasing incidence of inflammatory bowel disease is expected to propel the growth of the entyvio market going forward. Inflammatory bowel disease (IBD) is a group of chronic, relapsing inflammatory disorders of the gastrointestinal (GI) tract, characterized by immune system dysregulation, leading to prolonged inflammation and tissue damages. The increasing incidence of inflammatory bowel disease is due to a combination of genetic predisposition, environmental factors such as diet and urbanization, lifestyle changes including higher stress levels, and alterations in gut microbiota driven by factors such as antibiotic use and reduced exposure to natural microbes. Entyvio helps in treating inflammatory bowel disease (IBD) by targeting and blocking the alpha4beta7 integrin, which reduces the migration of inflammatory cells to the gut. For instance, in June 2024, the Centre for Disease Control and Prevention, a US- based non-profit organization, estimates that the prevalence of inflammatory bowel disease (IBD) in the United States ranges from 2.4 to 3.1 million people. Therefore increasing prevalence of inflammatory bowel disease is driving the growth of the entyvio market.
Rising Healthcare Expenditure Drives Market Growth for Entyvio
Rise in healthcare expenditure is expected to propel the growth of the entyvio market going forward. Healthcare expenditure refers to the total financial resources spent on health services and goods to maintain or improve the health of individuals and populations. The rising healthcare expenditure is due to factors such as the growing prevalence of chronic diseases, advancements in medical technology, an aging population requiring more intensive care, increased costs of prescription drugs and specialized treatments, and expanding access to healthcare services in both developed and developing regions. Healthcare expenditure supports entyvio by facilitating access to advanced biologic therapies for patients with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis, ensuring funding for its research, development, distribution, and integration into treatment protocols while promoting improved patient outcomes and healthcare system efficiency. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Thus, rise in healthcare expenditure is driving the growth of the entyvio market.
What emerging segments are shaping the future landscape of the entyvio industry?
The entyvio market covered in this report is segmented –
1) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
2) By Treatment Line: First-Line Therapy; Second-Line Therapy
3) By Indication: Ulcerative Colitis (UC); Crohn’s Disease (CD)
4) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/entyvio-global-market-report
What are the top market trends driving innovation in the entyvio industry?
The key trend in the entyvio market is focusing on developing maintenance therapies to improve the long-term management of inflammatory bowel disease (IBD). Maintenance therapies refer to ongoing treatments designed to manage chronic conditions, prevent disease progression, and sustain a stable or improved state of health after achieving initial therapeutic goals. These therapies aim to reduce the risk of relapses, complications, or symptoms over time, ensuring long-term disease control and improved quality of life for patients. For instance, in April 2024, Takeda pharmaceutical, a US based pharmaceutical company, received Food and Drug Administration, a US-based federal agency, approval for the subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) Entyvio. The subcutaneous option allows for self-administration using a pre-filled pen, making it more convenient for patients to manage their treatment at home after an initial IV infusion during the induction phase. Clinical studies have shown that Entyvio significantly improves symptoms and induces remission in patients with Crohn’s disease compared to placebo.
How are key players in the entyvio market strengthening their market position?
Major companies operating in the entyvio market include Takeda Pharmaceutical Company Limited
Which geographic areas are contributing significantly to the growth of the entyvio sector?
North America was the largest region in the Entyvio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the entyvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Entyvio Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19901
Need Customized Data On Entyvio Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19901&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
